The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Drug and Therapeutics Committee

Rationalization Clinical Trial

Official title:

The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Work of the Drug and Therapeutics Committee, Single-centre, Cost-minimisation Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04314336
• Other study ID #: 1520192020
• Status: Completed
• Start date: August 1, 2019
• Est. completion date: June 1, 2020

Study information

• Verified date: December 2020
• Source: Bjelovar General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators have performed cost-minimisation analysis and compared the expenses based on the plan for public procurement (without clinical pharmacist involvement) for drugs with the results of public procurement based on the revised plan for public procurement by the clinical pharmacist. The plan for public procurements was based on the 1 year quantity for each medicine used by the hospital in the previous year, based on the latest deliverable prices at the time of extracting the data to workbook for MS Excel program (ver. 2002, Microsoft, Redmond, WA, USA).

The investigators have performed cost-minimisation analysis and compared the expenses for all received requests for medicines to the drug and therapeutics committee (DTC) for a decision in the 1 year period, before and after involvement of clinical pharmacist in the committee work. The expenses were based on approval decisions in the 1 year period for approval time period. The denial decisions were also calculated and reported. The denial period calculated in rationalisation of expenses were based on 1 year treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10000
• Est. completion date: June 1, 2020
• Est. primary completion date: May 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 100 Years

Eligibility

Inclusion Criteria:

• All patients in the hospital (inhospital patients)

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Rationalization

Intervention

Drug:
• Public procurement
Cost minimisation study through public procurement
• Drug and Therapeutics Committee
Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement

Locations

Country	Name	City	State
Croatia	General Hospital Bjelovar	Bjelovar

Sponsors (1)

Lead Sponsor	Collaborator
Bjelovar General Hospital

Country where clinical trial is conducted

Croatia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reducing prices of medicines	Reduce prices of medicines in percentage, since different countries and hospitals have various budgets and medicine prices	1 year
Secondary	Rationalization of expenses	Rationalization of expenses through rquests for medicines sent to Drug and Therapeutics Committee	1 year